
Daraxonrasib is now approved in the second line and beyond in metastatic #PancreaticCancer in the European Union. Good news for patients across the pond! @RevMedicines @KRASKickers revmed.com/media/news/13736/…

Medical Oncologist focused on GI & Endocrine Malignances. Vall Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO). Teknon Cancer Institute.

Daraxonrasib is now approved in the second line and beyond in metastatic #PancreaticCancer in the European Union. Good news for patients across the pond! @RevMedicines @KRASKickers revmed.com/media/news/13736/…

Congratulations to @JHernando3 and co-authors on the publication of the latest ENETS consensus paper on somatostatin analogues and thank you, @OncoThor, for recommending it to the NET community!
OK, last NEN article post of the night (thanks, Delta, for excellent in-air wifi and for keeping me hypercaffeinated). This is a really cool paper, an @ENETS_ORG consensus paper led by @JHernando3, an expert panel, on unresolved clinical scenarios and emerging approaches with somatostatin analogues. Yes, I read it already! It is great, clinically helpful, hits many of the classic SSA controversies, and if you see patients with NETs, you should read it too... onlinelibrary.wiley.com/doi/…

🔊🔊 Daraxonrasib approved in EU !! New hope for #pancreaticcancer patients!! @_SEOM @VHIO @vallhebron @GrupoTTD @GEPAC_ @Alipanc1 @RevMedicines revmed.com/media/


OK, last NEN article post of the night (thanks, Delta, for excellent in-air wifi and for keeping me hypercaffeinated). This is a really cool paper, an @ENETS_ORG consensus paper led by @JHernando3, an expert panel, on unresolved clinical scenarios and emerging approaches with somatostatin analogues. Yes, I read it already! It is great, clinically helpful, hits many of the classic SSA controversies, and if you see patients with NETs, you should read it too... onlinelibrary.wiley.com/doi/…

🦓🔬 Becas GETNE | #GETNE2026 🎤 Dr. Alejandro García presenta la Beca R-GETNE 2022. 💊 Estreptozotocina vs quimioterapia basada en temozolomida en #TNE bien diferenciados. 📊 Datos de vida real. 💙 ¡Impulsando la investigación!

📣 Desde GETNE damos visibilidad a #NETPRACTICE 🌍 🔬 ¿Tratas pacientes con TNE? ¡Participa en esta encuesta internacional sobre práctica clínica y necesidades no cubiertas! 🌎 70 respuestas | 12 países ⏱️ 12–15 min | 🔒 Anónima 📊 Primeros resultados en #ENETS ✍️ docs.google.com/forms/d/e/1F… @Alej_GarciaMD @Ja_Capdevila @JHernando3

📣 Supporting #NETPRACTICE, an international initiative led by @Alej_GarciaMD @VHIO 🌍 🔬 Do you treat patients with #NETs? Share your clinical experience and unmet needs! 🌎 70 responses | 12 countries ⏱️ 12–15 min | 🔒 Anonymous 📊 First results at #ENETS 🔗 docs.google.com/forms/d/e/1F… @Alej_GarciaMD @JHernando3 @Ja_Capdevila @VHIO @GrupoGetne

Todo listo para recibir a asistentes, conferenciantes, pacientes e industria en #GETNE2026 en Córdoba 🔴 El simposio anual del Grupo Español de Tumores Neuroendocrinos y Endocrinos (@GrupoGetne) 🔴 Estudiar estos tumores infrecuentes requiere un abordaje multidisciplinar y esta reunión es el foro ideal.

Arranca el XXII Simposio @GrupoGetne !!!!! Enhorabuena a los organizadores por el esfuerzo y a pesar de las circunstancias!!! @_SEOM @Ja_Capdevila @JHernando3

🦓 ¡Arranca el XXII Simposio GETNE 2026 en Córdoba! 🎤 @Ja_Capdevila y Justo Castaño inauguran dos jornadas dedicadas a los avances científicos, la innovación y el abordaje multidisciplinar de los tumores neuroendocrinos. 🤝 ¡Bienvenidos a #GETNE26 !

🟢 En el #DíaMundialDeLosTumoresNeuroendocrinos, SEOM destaca... 🔊los avances en diagnóstico, radiofármacos, terapias dirigidas y quimioterapia que permiten individualizar cada vez más el tratamiento de los #TNE y mejorar el control de la enfermedad 🔗 seom.org/noticias/los-avance…

It takes a village to advance cancer research—and in this case, a truly GLOBAL village! 🌎 Grateful for the opportunity to present exciting new data from the Phase Ib DAREON-7 study at #NANETS2026, evaluating first-line obrixtamig (DLL3-targeted T-cell engager) + standard-of-care chemotherapy in extrapulmonary neuroendocrine carcinoma (epNEC). The results are incredibly encouraging in a disease where effective treatment options remain limited. 📊 Key highlights: Overall response rate: 77.3% across all patients DLL3-high tumors: 87.5% response rate! 12-month PFS: 47% in the DLL3-high population That last number is particularly striking. Nearly half of patients with DLL3-high tumors remained progression-free at one year on frontline—in a disease where median overall survival has historically been approximately one year. For those of us who care for patients with epNEC, these early signals are especially meaningful and offer genuine hope for improving outcomes in this aggressive malignancy. Excited to see this promising therapeutic strategy being evaluated in the definitive randomized Phase III DAREON-NEC-1 trial. Looking forward to seeing whether these encouraging early results translate into meaningful survival benefits in a larger, randomized population. #NANETS2026 #NeuroendocrineCarcinoma #NEC #DLL3 #Immunotherapy #ClinicalTrials #CancerResearch #TeamScience

🦓💙 ¡Hoy es el #DíaMundialDeLosTumoresNeuroendocrinos! 🧬 Más visibilidad. 🔬 Más investigación. 🤝 Más colaboración. 💙 Mejor atención a nuestros pacientes. Desde @GrupoGetne seguimos trabajando para avanzar juntos en el conocimiento y tratamiento de los #TNE.

⏳ ¡Solo faltan 3 días para el XXII Symposium GETNE 2026! 🧬 📍 Córdoba | 12 y 13 de noviembre Dos días para compartir avances, intercambiar experiencias y seguir impulsando la investigación y la colaboración multidisciplinar. 🤝 ¡Nos vemos en Córdoba! #GETNE26

@AmanChauhanMD presents very promising update for DAREON-7 (upfront chemotherapy + obrixtamig) - RR 77%, mDOR 12.5 mo, mPFS 7.7 mo (9.5 mo in DLL3-high). Phase 3 DAREON-NEC-1 underway…. #NANETS2026